This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The sensitivity of each screening modality was assumed to depend on tumour size and age at the time of test via a logit model. To assess the overall sensitivity of a screening policy using both mammography and CBE, the authors assumed that the two modalities were independent.
The estimates of outcomes were reported in Parmigiani et al. 2002 (see 'Other Publications of Related Interest' below for bibliographic details) and Shen et al. (in press ).
Measure of benefits used in the economic analysis
The measure of benefits used was the quality-adjusted life-year (QALY). For more information on the quality adjustments undertaken in the model, the authors referred the reader to Parmigiani et al. (1999) .
Direct costs
The authors adopted a public health perspective. The direct medical costs included in the analysis were for the examinations (i.e. mammography and CBE test costs). The authors did not explicitly consider the costs of false-positive exams, possible over-diagnosis, and the downstream financial consequences of early detection. They also did not report the sources from which the unit costs for the screening tests were derived. All the quantities of resources used were derived from the model. Discounting was not reported, although it would appear to be necessary as the costs of the screening programme could be incurred over future years (0.5-, 1-or 2-year intervals). The study reported the marginal costs. The price year was not reported.
Statistical analysis of costs
The costs were treated as point estimates (i.e. the data were deterministic).
Indirect Costs
The indirect costs were not included.
Currency

US dollars ($).
Sensitivity analysis
The authors performed sensitivity analyses by using different age-specific preclinical breast cancer duration distributions. The two cost scenarios considered were CBE at $100 and mammography at $200 or $150. Therefore, the authors investigated the effect of varying the cost ratio between CBE and mammography from 1.5 to 2.
Estimated benefits used in the economic analysis
The authors compared a total of 48 screening interventions. They estimated the marginal (or incremental) benefits of the screening strategy over those of no screening. The marginal benefit was reported for 18 alternatives of breast cancer screening, based on the combination of age at start (40 or 50 years), interval between examination (6 months, 1 year or 2 years), and whether mammography and CBE were given at every exam or at every two exams.
For each screening interval and starting age, giving mammography and CBE at every exam had the highest marginal benefit (i.e. additional QALYs) over no screening. This ranged from 0.055 additional QALYs when women started screening at age 50 and the interval of examination was every 2 years, to 0.221 additional QALYs when women started screening at age 40 and the interval of examination was every 6 months.
In contrast, for each screening interval and starting age, giving mammography every two exams and CBE at every exam had the lowest marginal benefit over no screening. This ranged from 0.050 additional QALYs when women started screening at age 50 and the interval of examination was every 2 years, to 0.195 additional QALYs when women started screening at age 40 and the interval of examination was every 6 months.
Cost results
The authors compared a total of 48 screening interventions. They estimated the marginal (or incremental) costs of the screening strategy over those of no screening. The marginal cost was reported for 18 alternatives of breast cancer screening.
For each screening interval and starting age, giving mammography every two exams and CBE at every exam had the lowest marginal cost over no screening. This ranged from an additional $2,400 when women started screening at age 50 and the interval of examination was every 2 years, to an additional $13,100 when women started screening at age 40 and the interval of examination was every 6 months.
In contrast, for each screening interval and starting age, giving mammography and CBE at every exam had the highest marginal cost over no screening. This ranged from an additional $3,700 when women started screening at age 50 and the interval of examination was every 2 years, to an additional $19,700 when women started screening at age 40 and the interval of examination was every 6 months.
Synthesis of costs and benefits
The costs and benefits were combined using an incremental cost-utility ratio (i.e. the additional cost per QALY saved). For each screening interval and starting age, giving mammography every two exams and CBE at every exam had the lowest marginal cost per QALY saved. This ranged from $48,600 per QALY saved when women started screening at age 50 and the interval of examination was 2 years, to $67,200 per QALY saved when women started screening at age 40 and the interval of examination was 6 months.
In contrast, giving both mammography and CBE at every exam had the highest marginal cost per QALY saved. This ranged from $66,900 per QALY saved when women started screening at age 50 and the interval of examination was 2 years, to $89,200 per QALY saved when women started screening at age 40 and the interval of examination was 6 months.
The results of the sensitivity analysis showed that varying the age-specific preclinical duration distributions did not alter the relative cost-effectiveness of the policies. The authors also reported that using a cost ratio of 2 between the costs of mammography and CBE increased the overall costs for each strategy, especially the strategies with relatively short screening intervals. However, such a change did not alter the relative cost-effectiveness of the policies.
Authors' conclusions
A biennial mammography coupled with an annual clinical breast examination (CBE) was the most cost-effective screening strategy for breast cancer.
CRD COMMENTARY -Selection of comparators
No justification was given for using no screening as the comparator. However, it would appear that this strategy has been used to evaluate the active value of the other 48 screening options. More importantly, the authors failed to compare the costs and outcomes of screening using both CBE and mammography with screening using mammography only, which is current practice in many European countries. You should decide if the comparator represents current practice in your own setting.
Validity of estimate of measure of effectiveness
quality of the study.
Validity of estimate of measure of benefit
The estimation of benefits was modelled. The authors used health utility (QALYs) as a measure of benefit in the economic analysis. The utility values were derived from the literature, but no specific details on the method used to derive them were reported in the current study. This makes it difficult to comment on the quality of the estimates used. Although discounting of the benefits would appear to have been relevant, the authors did not report if future benefits were discounted.
Validity of estimate of costs
The cost analysis was performed from a public health perspective. The authors only included the costs of actual screening for breast cancer. They did not consider other relevant costs, such as those associated with the consequences of early detection, over-diagnosis and false-positive exams. It is unclear if the overall impact of these omissions would have biased the results in favour or against the screening interventions. The costs and the quantities were not reported separately, which will limit the generalisability of the authors' results. The sources from which the unit costs were derived were not reported. The authors undertook limited sensitivity analyses of the costs by varying the cost ratio between mammography and CBE. Discounting appears to have been relevant, as part of the screening costs were incurred in the future, but the authors did not report discounting of future costs. The price year was not reported, which will hamper any future inflation exercises.
